Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA) - Concepedia

Concepedia

Publication | Open Access

Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA)

DOI Full Paper Access

27

Citations

19

References

2021

Year

Dmytro Trukhin, Elena Poddubskaya, Zoran Andrić, Tamta Makharadze, Ravi Shankar Bellala, Chaiyut Charoentum, Eduardo Patricio Yanez Ruiz, Andrea Fülöp, Irfhan Ali Hyder Ali, Kostas Syrigos,

References

	Year	Citations

Page 1